Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04501939
Title Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Diego

chronic lymphocytic leukemia/small lymphocytic lymphoma


Cirmtuzumab + Venetoclax

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.